Healthera

Leo Cancer Care provides a streamlined and effective treatment method that empowers patients and instills hope. Founded in Australia, Leo Cancer Care is grounded in international research on the advantages of upright patient positioning. Through a shift from machine rotation to patient rotation, Leo Cancer Care is positioned to revolutionize radiation therapy.

Neubond develops wearable devices for stroke mobility rehabilitation. These devices provide autonomous assistance and therapy during daily activities, integrating rehabilitation into the patient's daily life regardless of their motor capabilities. Neubond's solutions are designed to be intuitive and effective, aiming to improve the quality of life for individuals undergoing rehabilitation.

Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.

Nebu-Flow is a manufacturer of the next generation of inhaled drugs for patients with respiratory disorders. The company is a developer of the technology control of the droplet size for deep lung deposition by enabling injection-free systemic drug delivery through inhalation routes for cardiovascular and central nerve system disorders. Nebu-Flow is committed to minimizing the environmental impact of activities whilst continuing to create a user-friendly and high-performing Nebuliser.

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Innovative medical gadgets are created by Creo Medical Limited, situated in Chepstow, South Wales. With a variety of clinically useful tools, Creo Medical's distinctive bipolar radiofrequency and microwave energy platform enables precise tissue effects to be achieved. The first tool conducts flexible endoscopic dissection of gastrointestinal tract tissue anomalies. With the first set of tools, a flexible endoscope will be used to address a variety of issues in gastroenterology. The CROMA platform and product line will expand into new therapeutic spheres like laparoscopic surgery and the management of certain malignant lesions.

TympaHealth has developed the world's first ear and hearing health assessment system. The Tympa system empowers non-specialists to perform high definition digital otoscopy, microsuction wax removal and a hearing screening, all in a single 30 minute appointment. Users can also upload patient images and video to the secure cloud, where they can be reviewed by ENT specialists anywhere in the world.

NEX Health Intelligence (NEX) is a health-tech business that develops AI-powered software for hospitals to detect, track, and prevent illnesses, including drug-resistant epidemics.

Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.

Asterix Health is the workforce solution for modern healthcare.

Gloucester Rugby is a professional English rugby union club that gives up to date with all the information for men and women teams. Its local importance extends well beyond the city. It is a high-performing team that is recognised internationally and an average of 15,000 supporters.

PlaqueTec is pioneering the development of biomarker-based strategies to transform the prevention, diagnosis, and treatment of Coronary Artery Disease, the leading cause of death worldwide. As with any successful startup, PlaqueTec has a strong leadership team with a unified vision for continued growth, and a commitment to changing the current standard of care in the diagnosis, prevention, and treatment of CAD. They work closely with cardiologists, academic scientists, and biopharmaceutical companies around the world to advance understanding of CAD and the inflammatory processes underlying the progression of this common and dangerous disease, and to accelerate the testing of existing and new therapeutic agents for CAD.